Child and Adolescent Allergology, Women's and Children's Health, University of Uppsala, Uppsala, Sweden.
Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Ann Allergy Asthma Immunol. 2018 Jun;120(6):648-653.e1. doi: 10.1016/j.anai.2018.02.028. Epub 2018 Feb 27.
Epinephrine should be administered intramuscularly in the anterolateral aspect of the thigh. The length of the epinephrine auto-injector (EAI) needle should ensure intramuscular injection.
To discuss suitable EAI needle lengths based on ultrasound measurements related to weight.
The skin-to-muscle distance (STMD) and skin-to-bone distance (STBD) were measured by ultrasound in the mid-third of the anterolateral area of the right thigh when applying high pressure (8 lb; high-pressure EAI [HPEAI]) or low pressure (low-pressure EAI [LPEAI]) on the ultrasound probe. The study included 302 children and adolescents and 99 adults. The maximum and minimum STMD and the maximum and minimum STBD were estimated.
Using HPEAIs, the risk of periosteal or intraosseous penetration was 32% in children weighing less than 15 kg. The risk of subcutaneous injection was 12% in adolescents and 33% in adults. With LPEAIs, there was no risk of periosteal or intraosseous injection and the risk of subcutaneous injections in adolescents and adults was lower at 2% and 10%, respectively. A new EAI for injection in small children would have no risk of periosteal or intraosseous injection but would have 71% chance of subcutaneous deposit of epinephrine.
Common HPEAIs have a high risk of periosteal or intraosseous penetration in children and subcutaneous injections in overweight and obese adults. LPEAIs have some risk of subcutaneous injection in adults. HPEAIs with 0.1 mg of epinephrine and shorter needles have no risk of periosteal or intraosseous injection but have a high risk of subcutaneous deposit. For adult or overweight or obese patients, HPEAIs and LPEAIs should have longer needles. Future studies should focus on triggering pressures and variations in needle length.
肾上腺素应肌肉内注射于大腿前外侧。肾上腺素自动注射器(EAI)的针长应确保肌肉内注射。
根据与体重相关的超声测量结果,探讨合适的 EAI 针长。
在右大腿前外侧中三分之一处应用高压力(8 磅;高压力 EAI [HPEAI])或低压力(低压力 EAI [LPEAI])于超声探头时,通过超声测量皮肤-肌肉距离(STMD)和皮肤-骨距离(STBD)。研究纳入了 302 名儿童和青少年及 99 名成年人。估计了最大和最小 STMD 以及最大和最小 STBD。
使用 HPEAIs,体重小于 15kg 的儿童发生骨膜或骨内穿透的风险为 32%。青少年和成年人发生皮下注射的风险分别为 12%和 33%。使用 LPEAIs,无骨膜或骨内注射风险,青少年和成年人的皮下注射风险分别为 2%和 10%。一种新的用于小儿童注射的 EAI 无骨膜或骨内注射风险,但有 71%的机会将肾上腺素皮下沉积。
常见的 HPEAIs 在儿童中存在骨膜或骨内穿透的高风险,在超重和肥胖的成年人中存在皮下注射的高风险。LPEAIs 在成人中存在一定的皮下注射风险。含 0.1mg 肾上腺素且针更短的 HPEAIs 无骨膜或骨内穿透风险,但有皮下沉积的高风险。对于成年或超重或肥胖患者,HPEAI 和 LPEAI 应使用更长的针。未来的研究应重点关注触发压力和针长变化。